---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-26-000025"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2026-08-26T10:14:58+00:00"
generated_at: "2026-08-26T10:20:16.927380+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BeOne Medicines discloses H1 2026 R&D spend of $1.15B, up 14.6% YoY

## Summary
- Total R&D expense $1,153.5M in H1 2026 vs $1,006.8M in H1 2025, up 14.6% YoY.
- BRUKINSA R&D fell 33% to $42.7M from $63.0M; TEVIMRA down to $37.1M from $40.3M.
- BEQALZI (sonrotoclax) R&D $74.0M, down 21%; BGB-43395 CDK4 inhibitor surged to $22.7M vs $9.9M.
- Early-stage spend jumped: BGB-58067 $11.1M vs $1.9M, BG-C9074 $8.2M vs $2.4M, tacabrutideg $44.3M vs $26.9M.
- External R&D $435.1M vs $400.3M; internal R&D $718.4M vs $606.5M a year ago.

## SEC filing metadata
- accession: 0001651308-26-000025
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2026-08-26T10:14:58+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000025/0001651308-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000025/bgne-20260826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-26-000025
- JSON: https://secwatch.observer/filing/0001651308-26-000025.json
- Plain text: https://secwatch.observer/filing/0001651308-26-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.